ASCO GU 2024 Bladder Cancer

Viewing 1-20 of 53 articles

ASCO GU 2024: Biology of Tumor Types: Radiation Versus Surgery

ASCO GU 2024: Phase 3 Open-Label, Randomized, Controlled Study of Disitamab Vedotin with Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (DV-001)

ASCO GU 2024: Catalysts for Change: Patient Advocacy’s Role in Drug Shortages

ASCO GU 2024: Approach to the Platinum Shortage from a Community Oncologist Perspective

ASCO GU 2024: Phase 3 KEYNOTE-676 Cohort A: Bacillus Calmette-Guérin with or Without Pembrolizumab for High-Risk Non–muscle-Invasive Bladder Cancer That Persists/recurs After BCG Induction

ASCO GU 2024: Advanced Urothelial Carcinoma Discussant

ASCO GU 2024: Keynote Lecture - Charting New Paths: Increasing Patient Representation in Genitourinary Malignancy Trials

ASCO GU 2024: A New Era in the Perioperative Management of Muscle Invasive Bladder Cancer

ASCO GU 2024: Drug Sequencing, Pairing, Switching, and the Role of Checkpoint Re-Challenging

ASCO GU 2024: Drug Shortages: Why Are They a Recurrent Issue and What Can Regulatory Do to Prevent Them?

ASCO GU 2024: Lessons Learned: What Can Other Disease Sites Teach Us About Practical Implications of Checkpoint Therapy in Urothelial Carcinoma?

ASCO GU 2024: Surgical Therapeutic Role for Node-Positive Disease: Does It Make a Difference?

ASCO GU 2024: Harnessing the Power: Biologic Basis of Pairing and Sequencing Checkpoints with Other Therapy

ASCO GU 2024: Infigratinib vs Placebo in Patients with Resected Urothelial Cancer Bearing FGFR3 Mutation or Fusion: Primary DFS Analysis from the Phase 3, Randomized PROOF302 Study

ASCO GU 2024: Application of Artificial Intelligence Features of Nuclear Morphology from BLASST-1 (Bladder Cancer Signal Seeking Trial) of Nivolumab, Gemcitabine, and Cisplatin in Patients with MIBC Undergoing Cystectomy

ASCO GU 2024: RC48-ADC Versus BCG in Adjuvant Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer with HER2 Over-Expression: A Real-World Retrospective Study

ASCO GU 2024: Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD-1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations

ASCO GU 2024: Urinary Minimal Residual Disease Detection Predicts Recurrence in BCG-Unresponsive NIMBC and Quantifies Molecular Response to Nadofaragene Firadenovec

ASCO GU 2024: Population Based Trends in Intravesical Gemcitabine Use Among Patients with High-Risk Non-Muscle Invasive Bladder Cancer

ASCO GU 2024: Reasons for Refusal of or Ineligibility for Radical Cystectomy in Patients with BCG–unresponsive High-Risk NMIBC from the SunRISe-1 Study

1
2
3